Press Release: Synergy CHC Corp. Reports First Quarter 2026 Financial Results

Dow Jones
May 14

N. WINDHAM, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three months ended March 31, 2026.

"Our first quarter results reflect continued execution and the growing momentum of our functional beverage business," said Jack Ross, CEO of Synergy CHC Corp. "During the quarter, we generated over $650,000 in functional beverage revenue, exceeding our total beverage revenue for all of 2025. This performance reflects the success of our expanding retail and distribution partnerships across the U.S., supported by healthy sell-through that is already driving increased reorder activity. Reflecting this momentum, our beverage division is operating at an estimated annual run rate exceeding $4 million. With this foundation in place and continued expansion of our distribution footprint underway, we believe we are well-positioned to capture the significant growth opportunities emerging within the functional beverage sector. With solid early-year momentum and a clear strategic path, we expect 2026 to be a year of sustainable growth and value creation for our shareholders."

First Quarter 2026 Financial Summary vs. Same Year-Ago Period

   -- Revenue of $5.49 million vs. $8.17 million. 
 
   -- Gross margin of 72.3% vs. 75.4%. 
 
   -- Income (loss) from operations of ($0.57) million vs. $1.95 million. 
 
   -- Net income (loss) of ($2.57) million vs. $0.88 million. 
 
   -- Earnings (loss) per share of ($0.23) vs. $0.10. 
 
   -- EBITDA (loss), a non-GAAP financial measure, was ($0.54) million vs. 
      $1.98 million. 
 
   -- Adjusted EBITDA (loss), a non-GAAP financial measure, was $(0.35) million 
      vs. $1.98 million. 

First Quarter 2026 Financial Results

Revenue in the first quarter of 2026 was $5.49 million compared to $8.17 million in the first quarter of 2025, due to license revenue of $1.5 million in 2025 that did not repeat in 2026 and out-of-stock dynamics for several key online items in our Flat Tummy brand, which impacted online sales. This was partially offset by strong performance in beverages, which delivered significantly higher revenue compared to the prior year period.

Gross margin in the first quarter of 2026 was 72.3% compared to 75.4% in the first quarter of 2025. Excluding license revenue from the first quarter of 2025, normalized gross margin for that period was 70.0%, a 2.3% improvement year-over-year.

Operating expenses in the first quarter of 2026 were $4.54 million compared to $4.22 million in the first quarter of 2025, reflecting higher overhead associated with the expansion of the beverage business.

Income (loss) from operations for the first quarter of 2026 was ($0.57) million compared to $1.95 million in the first quarter of 2025, which is largely due to the license revenue of $1.5 million in 2025 that did not repeat in 2026 and increased overhead costs.

Net income (loss) in the first quarter of 2026 was ($2.57) million compared to net income of $0.88 million in the first quarter of 2025.

Earnings (loss) per share in the first quarter of 2026 was ($0.23) compared to $0.10 in the first quarter of 2025.

EBITDA (loss) (a non-GAAP financial measure) in the first quarter of 2026 was ($0.54) million compared to $1.98 million in the first quarter of 2025.

Adjusted EBITDA (loss) (a non-GAAP financial measure) in the first quarter of 2026 was $(0.35) million compared to $1.98 million in the first quarter of 2025.

Balance Sheet and Cash Flow

As of March 31, 2026, Synergy had approximately $0.30 million in cash and cash equivalents, compared to $2.6 million in cash and cash equivalents as of December 31, 2025. Subsequent to quarter-end, Synergy raised approximately $2.7 million in gross proceeds through its at-the-market (ATM) equity offering program.

As of March 31, 2026, Synergy had a working capital deficit of $0.50 million, compared to a $1.78 million working capital surplus as of December 31, 2025.

As of March 31, 2026, Synergy had $3.4 million in inventory, compared to $3.7 million in inventory as of December 31, 2025.

Cash used in operating activities for the three months ended March 31, 2026 was $2.0 million compared to cash used in operating activities of $0.82 million for the three months ended March 31, 2025.

Non-GAAP Financial Measure Reconciliation: EBITDA and Adjusted EBITDA

To assist financial statement users in an assessment of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and related events, as the Company believes that the non-GAAP information enhances investors' overall understanding of our financial performance, and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP.

Management believes EBITDA and Adjusted EBITDA provide useful information to investors by excluding certain items that may not be indicative of the Company's core operating results and that can vary significantly between periods. EBITDA is defined as net income plus interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA is calculated as EBITDA plus or minus foreign exchange gains or losses, one-time expenses and non-cash expenses. Since Adjusted EBITDA is a non-GAAP financial performance measure, the Company's calculation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies; and should not be considered in isolation, as a substitute for, or superior to measures of financial performance prepared in accordance with GAAP.

The following table reconciles net income to EBITDA and Adjusted EBITDA (in millions of US dollars):

 
 
                                         3 Months ended March 31 
                                             2026         2025 
                                          -----------   --------- 
 
  Net (loss) income for the period     $       (2.57)  $     0.88 
                                          -----------   --------- 
  Adjusted for: 
                                      ---------------  ------------ 
  Interest expense, net                          2.01        1.08 
                                          -----------   --------- 
  Amortization of intangible assets              0.03        0.03 
------------------------------------      -----------   --------- 
  Tax benefit                                  (0.01)      (0.01) 
                                          -----------   --------- 
  EBITDA                               $       (0.54)  $     1.98 
  Foreign currency adjustment                   (0.00        0.00 
  Stock based compensation                       0.16           - 
  Board expenses                                 0.03           - 
  Adjusted EBITDA                      $       (0.35)  $     1.98 
                                          -----------   --------- 
 

About Synergy CHC Corp.

Synergy CHC Corp. develops and markets consumer health and wellness products, led by its flagship brands FOCUSfactor$(R)$ and Flat Tummy(R) . FOCUSfactor(R) , a clinically studied brain health supplement and functional beverage line with a 25-year legacy, enjoys established distribution in the U.S., Canada and Mexico. through major retailers including Costco, Walmart, Amazon, BJ's, and Walgreens, among others. Flat Tummy(R) complements Synergy's portfolio as a lifestyle brand focused on women's wellness and weight management.

Forward Looking Statements

Certain statements contained in this press release constitute "forward-looking statements," including statements regarding brand expansion and growth initiatives. These forward-looking statements represent Synergy's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy's registration statement on Form S-1, as amended, many of which are outside of Synergy's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.

Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Synergy's filings with the SEC. The risk factors and other factors noted in Synergy's filings could cause its actual results to differ materially from those contained in any forward-looking statement.

Investor Relations

Gateway Group

Cody Slach, Greg Robles

949.574.3860

SNYR@gateway-grp.com

 
Synergy CHC Corp. 
 Condensed Consolidated Balance Sheets 
 
                                                     December 31, 
                                 March 31, 2026          2025 
                                  (unaudited) 
Assets 
Current Assets 
Cash and cash equivalents        $       292,115   $      2,622,313 
Restricted cash                          100,000            100,000 
Accounts receivable, net               1,268,022          3,203,505 
  Prepaid expenses (including 
   related party amount of 
   $652,270 and $110,803, 
   respectively)                       1,303,173            351,049 
Inventory, net                         3,381,614          3,737,509 
Total Current Assets                   6,344,924         10,014,376 
 
Intangible assets, net                   116,667            150,000 
 
Total Assets                     $     6,461,591   $     10,164,376 
 
Liabilities and Stockholders' 
Deficit 
Current Liabilities: 
  Accounts payable and accrued 
   liabilities (including 
   payable to shareholder of 
   $193,641 and $197,512, 
   respectively)                 $     4,031,994   $      6,388,219 
Income taxes payable                      85,811             88,108 
Contract liabilities                           -              1,526 
Short term loans payable, net 
 of debt discount, related 
 party                                         -            100,000 
Current portion of notes 
 payable, net of debt 
 discount                              2,730,981          1,658,215 
Total Current Liabilities              6,848,786          8,236,068 
 
Long-term Liabilities: 
Notes payable, net of debt 
 discount                             25,018,055         25,056,446 
Total long-term liabilities           25,018,055         25,056,446 
Total Liabilities                     31,866,841         33,292,514 
 
Commitments and contingencies 
 
Stockholders' Deficit: 
  Common stock, $0.00001 par 
   value; 300,000,000 shares 
   authorized; 11,483,926 
   shares issued; 11,303,853 
   outstanding                               114                114 
Additional paid in capital            33,710,857         33,594,550 
Common stock to be issued                153,400                  - 
Accumulated other 
 comprehensive loss                     (132,201)          (154,281) 
Accumulated deficit                  (59,009,920)       (56,441,021) 
Less: Treasury stock (180,073 
 shares) at cost                        (127,500)          (127,500) 
Total stockholders' deficit          (25,405,250)       (23,128,138) 
Total Liabilities and 
 Stockholders' Deficit           $     6,461,591   $     10,164,376 
 
 
Synergy CHC Corp. 
 Unaudited Condensed Consolidated Statements of Operations 
 and Comprehensive (Loss) Income 
 
                                      For the           For the 
                                    three months      three months 
                                       ended             ended 
                                     March 31,         March 31, 
                                        2026              2025 
Revenue 
Product Sales                      $    5,492,705   $     6,670,534 
License Revenue                                 -         1,500,000 
Total Revenue                           5,492,705         8,170,534 
 
Cost of Sales                           1,521,910         2,006,513 
 
Gross Profit                            3,970,795         6,164,021 
 
Operating expenses 
Selling and marketing                   2,455,732         2,876,271 
General and administrative              2,048,850         1,306,714 
Depreciation and amortization              33,333            33,333 
Total operating expenses                4,537,915         4,216,318 
 
(Loss) Income from operations            (567,120)        1,947,703 
 
Other (income) expenses 
Interest income                              (340)          (13,882) 
Interest expense                        2,012,121         1,095,369 
Remeasurement loss on 
 translation of foreign 
 subsidiary                                 3,718             1,412 
 
Total other expenses                    2,015,499         1,082,899 
 
Net (loss) income before income 
 taxes                                 (2,582,619)          864,804 
Income tax benefit                         13,720            11,460 
 
Net (loss) income after tax        $   (2,568,899)  $       876,264 
 
Net (loss) income per share -- 
 basic                             $        (0.23)  $          0.10 
Net (loss) income per share -- 
 diluted                           $        (0.23)  $          0.10 
 
Weighted average common shares 
outstanding 
Basic                                  11,303,853         8,560,636 
Diluted                                11,303,853         8,577,620 
Comprehensive (loss) income: 
Net (loss) income                  $   (2,568,899)  $       876,264 
Foreign currency translation 
 adjustment                                22,080            (1,935) 
Comprehensive (loss) income        $   (2,546,819)  $       874,329 
 
 
Synergy CHC Corp. 
 Unaudited Condensed Consolidated Statements of Cash 
 Flows 
 
                                        For the           For the 
                                      three months      three months 
                                         ended             ended 
                                       March 31,         March 31, 
                                          2026              2025 
Cash Flows from Operating 
Activities 
Net (loss) income                    $   (2,568,899)   $      876,264 
Adjustments to reconcile net 
(loss) income to net cash used in 
operating activities: 
Amortization of debt discount and 
 debt issuance cost                         951,942           406,841 
Depreciation and amortization                33,333            33,333 
Stock based compensation                    116,307                 - 
Foreign currency transaction loss 
 (gain)                                       2,684            (3,137) 
Remeasurement loss (gain) on 
 translation of foreign 
 subsidiary                                   3,718            (1,412) 
Changes in operating assets and 
liabilities: 
Accounts receivable                       1,935,483           940,519 
Other receivables                                 -           144,637 
Loan receivable, related party                    -              (833) 
Inventory                                   355,895          (629,935) 
Prepaid expenses                           (410,657)         (114,787) 
Prepaid expense, related party             (541,467)         (195,913) 
Income taxes payable                         (2,297)         (165,413) 
Contract liabilities                         (1,526)          (24,216) 
Accounts payable and accrued 
 liabilities                             (1,915,323)       (2,218,041) 
Accounts payable, related party              (3,871)          129,312 
Net cash used in operating 
 activities                              (2,044,678)         (822,781) 
 
Cash Flows from Investing 
Activities                                        -                 - 
 
Cash Flows from Financing 
Activities 
Advances from related party                       -           135,000 
Repayment of notes payable, 
 related party                             (100,000)                - 
Proceeds from notes payable               2,660,000         1,496,250 
Payment of loan financing fees              (55,000)                - 
Repayment of notes payable               (2,812,600)       (1,316,572) 
Net cash (used in) provided by 
 financing activities                      (307,600)          314,678 
 
Effect of exchange rate on cash, 
 cash equivalents and restricted 
 cash                                        22,080            (1,935) 
Net decrease in cash, cash 
 equivalents and restricted cash         (2,330,198)         (510,038) 
 
Cash and restricted cash, 
 beginning of year                        2,722,313           787,920 
Cash and restricted cash, end of 
 period                              $      392,115    $      277,882 
 
Supplemental Disclosure of Cash 
Flow Information: 
Cash paid during the period for: 
Interest                             $      392,846    $      573,529 
Income taxes                         $            -    $            - 
 
Supplemental Disclosure of 
Noncash Investing and Financing 
Activities: 
Issuance of common stock for 
 accounts receivable advance 
 financing                           $            -    $      117,648 
Loan financing fees, accrued         $      110,000    $            - 
Capitalized interest on senior 
 debt                                $      400,033    $            - 
Common stock to be issued for 
 accounts receivable advance 
 financing                           $      153,400    $            - 
 

(END) Dow Jones Newswires

May 14, 2026 08:00 ET (12:00 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10